You are here: Home » Companies » News
Emami faces weak earnings visibility, margin pressure; avoid bottom-fishing
Amazon Pay, ICICI launch new credit card as US firm eyes fintech expansion
Business Standard

Johnson & Johnson loses cancer drug patent, Indian firms eye US market

Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga

Topics
Glenmark  |  Wockhardt  |  Us Food And Drug Administration

Sohini Das  |  Mumbai 



Johnson & Johnson

With pharmaceutical major (J&J) losing the patent battle in the US court for its popular prostrate cancer drug Zytiga, opportunities for Indian players, who have already lined up generic versions, have opened up.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Wed, October 31 2018. 05:30 IST

RECOMMENDED FOR YOU

.